M&A / Deals Blackstone closes $6.3B fund for life sciences investing BioPharma DiveIt's the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.M&A / DealsRead full story pharminent March 30, 2026 (Last updated: March 31, 2026) BioPharma Dive It’s the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle. M&A / DealsRead full story Post navigation Previous: Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 ReadoutNext: S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026